Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2021.0379
Abstract: Importance Women may respond differently to certain treatments for heart failure (HF) with reduced ejection fraction (HFrEF) than men. Objective To investigate the efficacy and safety of dapagliflozin compared with placebo in men and women… read more here.
Keywords: ejection fraction; heart; heart failure; men women ... See more keywords
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2021.0660
Abstract: Importance Sodium-glucose cotransporter 2 inhibitors, such as dapagliflozin, promote renal glucose excretion and reduce cardiovascular (CV) deaths and hospitalizations for heart failure (HHF) among patients with type 2 diabetes. The relative CV efficacy and safety… read more here.
Keywords: patients type; death; hhf; type diabetes ... See more keywords
Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2022.2006
Abstract: Importance Dapagliflozin was shown to reduce the cardiovascular (CV) and kidney outcomes in patients with type 2 diabetes. However, data are limited on the relationship of the effect and safety with the concurrent use of… read more here.
Keywords: patients type; safety; kidney; type diabetes ... See more keywords
Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Cardiology"
DOI: 10.1001/jamacardio.2022.3736
Abstract: This pooled analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) and Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trials investigates the effect… read more here.
Keywords: ejection fraction; heart failure; dapagliflozin;
Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction
Sign Up to like & getrecommendations! Published in 2024 at "JAMA Cardiology"
DOI: 10.1001/jamacardio.2023.5318
Abstract: Key Points Question What is the mode of death and the association of dapagliflozin with cause-specific death in patients with heart failure with improved ejection fraction (HFimpEF)? Findings In this post hoc analysis of the… read more here.
Keywords: failure improved; dapagliflozin; mode death; improved ejection ... See more keywords
Effect of Multiple Doses of Sparsentan on the Single‐Dose Pharmacokinetics of Dapagliflozin: An Open‐Label Drug–Drug Interaction Study in Healthy Adults
Sign Up to like & getrecommendations! Published in 2023 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1231
Abstract: Sparsentan is a single‐molecule dual antagonist of the endothelin type A receptor and angiotensin II type 1 receptor under investigation for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. Dapagliflozin, a sodium‐glucose cotransporter… read more here.
Keywords: effect; sparsentan single; healthy adults; drug ... See more keywords
Rationale and Design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of heart failure"
DOI: 10.1002/ejhf.2370
Abstract: AIMS Despite aortic stenosis (AS) relief, patients undergoing transcatheter aortic valve implantation (TAVI) are at increased risk of developing heart failure (HF) within first months of intervention. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have been shown… read more here.
Keywords: valve implantation; aortic valve; dapagliflozin; transcatheter aortic ... See more keywords
Dapagliflozin Pharmacokinetics Is Similar in Adults with Type 1 and Type 2 Diabetes Mellitus.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.2062
Abstract: Dapagliflozin improves glycemic control in patients with type 2 diabetes mellitus (T2DM) and is approved in Japanese patients with type 1 diabetes mellitus (T1DM) with inadequate glycemic control. The objectives of this work were to… read more here.
Keywords: patients t1dm; dapagliflozin systemic; dapagliflozin pharmacokinetics; type diabetes ... See more keywords
Cost–Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand
Sign Up to like & getrecommendations! Published in 2022 at "Advances in Therapy"
DOI: 10.1007/s12325-021-02037-6
Abstract: Chronic kidney disease (CKD) creates a significant economic burden on patients and society. The DAPA-CKD trial reports the benefit of dapagliflozin in CKD patients; however, its cost-effectiveness is unknown in Thailand. This study evaluated the… read more here.
Keywords: cost; ckd; thailand; chronic kidney ... See more keywords
Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes Therapy"
DOI: 10.1007/s13300-021-01176-x
Abstract: To compare the efficacy and tolerability of dapagliflozin with those of sitagliptin and metformin in patients with type 2 diabetes who have never received glucose-lowering agents. In this randomized, 12-week, open-label, active-controlled trial, 32 patients… read more here.
Keywords: patients type; week; sitagliptin metformin; type diabetes ... See more keywords
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial
Sign Up to like & getrecommendations! Published in 2018 at "American Heart Journal"
DOI: 10.1016/j.ahj.2018.01.012
Abstract: Background: Dapagliflozin is a sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitor that reduces blood glucose in patients with type 2 diabetes mellitus (T2DM) by promoting glycosuria via inhibiting urinary glucose reabsorption. In addition to improving blood glucose control,… read more here.
Keywords: composite death; trial; declare timi; cardiovascular events ... See more keywords